We measured neovascularization, epidermal growth factor receptor, and c-erbB-2 expression in a consecutive series of 233 surgically resected axillary lymph node-negative breast cancer patients with a long-term follow-up to define the usefulness of these parameters as independent prognostic indicators of overall survival (OAS). Microvessel count (MVC), as a measure of neovascularization, was determined using a monoclonal antibody against human factor VIII-related antigen. The median MVC of 20 (range, 4–76) was used as a cutoff value for discriminating between low and high vascularized tumors. Epidermal growth factor receptor and c-erbB-2 expression were evaluated by immunohistochemistry. Tumors were considered positive if >10% of the cells showed specific membrane staining. OAS curves were estimated by the Kaplan-Meier method. The indepen-dent prognostic effect of each variable was determined with the Cox proportional hazards model. High MVC (P 5 0.04), high nuclear grade (P 5 0.005), and high S-phase (P 5 0.02) significantly affected OAS at univariate analysis. In a Cox multivariate analysis, the characteristics with an independent prognostic effect on OAS were: MVC (relative hazard, 2.12; 95% confidence interval, 1.18 –3.81; P 5 0.01) and nuclear grade (relative hazard, 2.83; 95% confidence interval, 1.12–7.17; P 5 0.01). These results demonstrate that quantification of neovascularization adds useful independent prognostic information on survival in node-negative breast cancer patients with long-term follow-up.

Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up / DE PLACIDO, Sabino; Carlomagno, Chiara; Ciardiello, F; DE LAURENTIIS, Michelino; Pepe, Stefano; Ruggiero, A; Tortora, Giampaolo; Panico, L; D’ ANTONIO, A; Pettinato, Guido; Petrella, Giuseppe; Bianco, Ar. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - STAMPA. - 5:10(1999), pp. 2854-2859.

Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up.

DE PLACIDO, SABINO;CARLOMAGNO, Chiara;DE LAURENTIIS, MICHELINO;PEPE, STEFANO;TORTORA, GIAMPAOLO;PETTINATO, GUIDO;PETRELLA, GIUSEPPE;
1999

Abstract

We measured neovascularization, epidermal growth factor receptor, and c-erbB-2 expression in a consecutive series of 233 surgically resected axillary lymph node-negative breast cancer patients with a long-term follow-up to define the usefulness of these parameters as independent prognostic indicators of overall survival (OAS). Microvessel count (MVC), as a measure of neovascularization, was determined using a monoclonal antibody against human factor VIII-related antigen. The median MVC of 20 (range, 4–76) was used as a cutoff value for discriminating between low and high vascularized tumors. Epidermal growth factor receptor and c-erbB-2 expression were evaluated by immunohistochemistry. Tumors were considered positive if >10% of the cells showed specific membrane staining. OAS curves were estimated by the Kaplan-Meier method. The indepen-dent prognostic effect of each variable was determined with the Cox proportional hazards model. High MVC (P 5 0.04), high nuclear grade (P 5 0.005), and high S-phase (P 5 0.02) significantly affected OAS at univariate analysis. In a Cox multivariate analysis, the characteristics with an independent prognostic effect on OAS were: MVC (relative hazard, 2.12; 95% confidence interval, 1.18 –3.81; P 5 0.01) and nuclear grade (relative hazard, 2.83; 95% confidence interval, 1.12–7.17; P 5 0.01). These results demonstrate that quantification of neovascularization adds useful independent prognostic information on survival in node-negative breast cancer patients with long-term follow-up.
1999
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up / DE PLACIDO, Sabino; Carlomagno, Chiara; Ciardiello, F; DE LAURENTIIS, Michelino; Pepe, Stefano; Ruggiero, A; Tortora, Giampaolo; Panico, L; D’ ANTONIO, A; Pettinato, Guido; Petrella, Giuseppe; Bianco, Ar. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - STAMPA. - 5:10(1999), pp. 2854-2859.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/167222
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 13
social impact